Bard enters $1bn surgical sealant market with Neomend buy
This article was originally published in Clinica
Executive Summary
CR Bard has agreed to buy surgical sealant specialist Neomend in a deal worth up to $165 million and which would "significantly expand" its Davol surgical subsidiary. Bard will pay $140 million upfront plus up to $25 million in revenue-based milestones until 2016.